CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential.
Koh CH, Lee S, Kwak M, Kim BS, Chung Y. · 2023
Read CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. by Koh CH, Lee S, Kwak M, Kim BS, Chung Y. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10689838.txt.
Introduction
Koh and co-authors reviewed CD8 T cell subsets in 2023, a branch of killer immune cells. These cells hunt infected or cancerous cells and kill them. After they meet a target, plain CD8 cells gain skills to strike. The classic view held one main killer subset.
Fresh proof splits the killers into distinct subsets, Koh reports. Each subset has its own mix of attack signals and toxic parcels. Each also plays a distinct part in infection, cancer, and other diseases. That split may explain why some immune drugs help one patient and miss the next. Drugs tuned to one subset could sharpen care, the authors argue. The review maps each subset and its known jobs.
Catalog record
| CREATOR | Koh CH, Lee S, Kwak M, Kim BS, Chung Y. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential By Choong-Hyun Koh, Suyoung Lee, Minkyeong Kwak, Byung-Seok Kim, Yeonseok Chung Published in: Experimental & Molecular Medicine DOI: 10.1038/s12276-023-01105-x ABSTRACT Abstract CD8 T cells play crucial roles in immune surveillance and defense against infections and cancer. After encountering antigenic stimulation, naïve CD8 T cells differentiate and acquire effector functions, enabling them to eliminate infected or malignant cells. Traditionally, cytotoxic T cells, characterized by their ability to produce effector cytokines and release cytotoxic granules to directly kill target cells, have been recognized as the constituents of the predominant effector T-cell subset. However, emerging evidence suggests distinct subsets of effector CD8 T cells that each exhibit unique effector functions and therapeutic potential. This review highlights recent advancements in our understanding of CD8 T-cell subsets and the contributions of these cells to various disease pathologies. Understanding the diverse roles and functions of effector CD8 T-cell subsets is crucial to discern the complex dynamics of immune responses in different disease settings. Furthermore, the development of immunotherapeutic approaches that specifically target and regulate the function of distinct CD8 T-cell subsets holds great promise for precision medicine. Subject terms: Lymphocyte differentiation, Interleukins INTRODUCTION Conventional T cell populations consist of CD4 T cells and CD8 T cells that recognize cognate antigenic peptides presented by MHC class II and I molecules, respectively. Typically, CD4 T cells orchestrate overall immune responses through interactions with professional antigen-presenting cells, whereas CD8 T cells exhibit direct cytotoxicity against target cells. CD8 T cells are derived from lymphoid progenitor cells in the bone marrow and undergo further maturation in the thymus. Thymic mature CD8 T cells, known as naïve CD8 T cells, are poised to be activated after encountering specific antigens. Recent studies have highlighted the phenotypic and functional diversity among naïve CD8 T cells, revealing their heterogeneity1. The cytotoxicity-inducing ability of CD8 T cells was initially discovered in the infectious disease context2–6. After infection, naïve CD8 T cells proliferate and differentiate into effector CD8 T cells, enabling them to efficiently eliminate infected cells and protect the host from severe infection. Following antigen clearance, a fraction of effector CD8 T cells differentiate into memory cells, which can immediately proliferate upon re-exposure to the antigen, ensuring a swift and robust immune response7–10. However, when CD8 T cells are subjected to persistent antigen stimulation, as seen in chronic viral infections or tumors, they become exhausted, impairing their responses to subsequent antigen stimulation11–13. Extensive research has focused on discerning the cellular biology of CD8 T cells driven by their potent cytotoxicity-inducing capacities, which has significantly advanced the field of tumor immunotherapy. This progress has led to the development of numerous immunotherapeutic strategies that harness the potential of CD8 T cells. The discovery of the cytotoxic function of CD8 T cells has paved the way for innovative therapeutic approaches. One prominent approach is adoptive cell therapy, which involves the isolation of CD8 T cells from patients and their subsequent ex vivo expansion and activation before being reintroduced back into the patient14,15. Specifically, significant strides have been made in the field of chimeric antigen receptor (CAR)-T-cell therapy, which involves genetically engineered patient CD8 T cells that effectively recognize cancer antigens. To date, the FDA has approved and clinically utilized more than six types of CAR-T-cell therapies for the treatment of certain types of hematologic malignancies16,17. Additionally, immune checkpoint inhibitors have emerged as a groundbreaking immunotherapeutic strategy that unleashes the full potential of CD8 T cells in response to tumors. By blocking inhibitory receptors, such as programmed cell death protein-1 (PD-1) or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), inhibitors restore the activity of CD8 T cells and promote their antitumor responses. This approach has shown remarkable success in certain types of cancer and has revolutionized the field of cancer immunotherapy. Although many studies have traditionally been focused on cytotoxic CD8 T cells, also known as Tc1 cells, which are characterized by their production of cytolytic cytokines such as IFN-γ, granzyme B, and TNF-α, recent investigations have revealed additional subsets of effector CD8 T cells, each with distinct characteristics that differ from those of Tc1 cells. The cells in these subsets demonstrate reduced cytotoxicity but produce a diverse array of cytokines and express transcription factors that are similar to those expressed in CD4 T-cell subsets, suggesting that their effects extend beyond directly induced cytotoxicity. These cells play a pivotal role in triggering cytokine-mediated effector functions and actively participate in immune regulation and tissue homeostasis maintenance. Furthermore, they may contribute to the modulation of immune responses, the orchestration of inflammatory processes, and the coordination of immune cell interactions. CYTOTOXIC CD8+ T CELLS (TC1 CELLS) As typical cytotoxic CD8+ T cells, Tc1 cells produce perforin, granzyme B, IFN-γ, and TNF-α, which enable them to eliminate tumor and infected cells. The activation of Tc1 cells is promoted by IL-12, which is produced by antigen-presenting cells exposed to pathogen-derived maturation-promoting stimuli. Several key transcription factors, such as STAT4, T-bet, and EOMES, contribute to the polarization of Tc1 cells14,18. Activated Tc1 cells have traditionally been thought to kill tumor or infected cells through mechanisms involving perforin-granzyme and Fas-FasL signaling. However, recent studies suggest that Tc1 cells kill target cells through additional cytotoxic pathways, including ferroptosis and pyroptosis19. Tc1 cells constitute the most prevalent subset of tumor-infiltrating lymphocytes in multiple types of cancers, including lung cancers20, breast cancers21, and chronic lymphocytic leukemia22, and are associated with favorable prognoses23–27. Tumors exhibiting a high degree of infiltration by Tc1 cells that subsequently produced elevated levels of IFN-γ are referred to as “hot” tumors. These “hot” tumors exhibit a more favorable response to immunotherapies than “cold” tumors, which lack Tc1 cell infiltration28,29. The expression of CD29 is associated with the increased cytotoxic potential of Tc1 cells in melanoma patients, suggesting that CD29 is a novel marker for the cytotoxic potency of Tc1 cells30. The significance of Tc1 cells has also been established in the viral disease contexts, including patients infected with measles virus, cytomegalovirus, hepatitis C virus, and human immunodeficiency virus (HIV)31–34. Following the clearance of infected cells, effector Tc1 cells can differentiate into memory cells7. Memory Tc1 cells retain the cytotoxic phenotype of effector Tc1 cells35 and readily produce IFN-γ upon reactivation36. Even in antigen-naive mice, a population of memory-like Tc1 cells, namely, CD44hiCD122hiCD8+ T cells, which are different from naïve T cells, can rapidly produce IFN-γ in response to TCR stimulation37–39. These cells exhibit a distinct epigenetic pattern on the Ifng promoter, suggesting that cytokine production may be regulated at the transcriptional level independent of previous antigen exposure-induced cell priming. Memory Tc1 cells are crucial for protection against cancer and infection40,41. In particular, stem cell-like memory T cells show superior antitumor immunity compared to effector T cells40. Moreover, memory Tc1 cells are relatively unaffected by the inhibitory effects of regulatory T cells (Tregs) in the tumor microenvironment42. Thus, the frequency of memory Tc1 cells has been proposed to be a potential predictive marker for responsiveness to ICI treatment43–45. Persistent antigen stimulation induces a state of exhaustion in effector Tc1 cells, leading to impaired cytolytic molecule production11. A single-cell transcriptome analysis revealed TOX as a key exhaustion-promoting transcription factor in human cancer46. Exhausted Tc1 cells display upregulated protein expression of TOX, which